HIGHLIGHTS
- who: Jun Li and collaborators from the Sant`Orsola-Malpighi Polyclinic, Italy University of Siena, Italy have published the article: High efficacy of azacitidine combined with homoharringtonine, idarubicin, and cytarabineu00a0in newly diagnosed patients with AML: A single arm, phase 2 trial, in the Journal: (JOURNAL)
- what: Discussion: This study provides preliminary evidence for this novel combination therapy as the first-line induction therapy for young or older AML patients fit for IC. This study was approved by the Institutional Review Board (approval code: 2019ZDSYLL211-P01) and all patients provided written informed consent before enrollment according . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.